Apricoxib

Apricoxib

Systematic (IUPAC) name
4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
Identifiers
CAS Number	162011-90-7
PubChem	CID 9820073
ChemSpider	7995822
Chemical data
Formula	C19H20N2O3S
Molar mass	356.4387 g/mol
SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) Key:JTMITOKKUMVWRT-UHFFFAOYSA-N

Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.^[1]

See also

• Tilmacoxib
• cimicoxib
• NS-398
• Celecoxib

References

1. Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453.